AUPH
Aurinia Pharmaceuticals Inc.
$16.22
+0.73 (+4.71%)
At close · Jul 7
Market Cap
$2.09B
Shares
128,601,671
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$283.06M
+20.4%
FY2025
Net Income
$287.2M
+4851.7%
FY2025
Gross Margin
88.46%
+0.5pp
FY2025
Operating Margin
37.06%
+39pp
FY2025
Diluted EPS
$2.07
+5075%
FY2025
Operating Cash Flow
$135.66M
+205.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| $315M – $325M | $298.3M | $283.06M | $235.13M | $175.51M | $134.03M | $45.61M | $50.12M | $318K | $463K | |
| — | $30.6M | $32.67M | $28.25M | $14.15M | $5.66M | $1.09M | $0 | $0 | — | |
| — | $267.7M | $250.39M | $206.89M | $161.37M | $128.37M | $44.51M | $50.12M | $318K | — | |
| — | — | 88.46% | 87.99% | 91.94% | 95.77% | 97.61% | 100% | 100% | — | |
| — | $34.23M | $32.51M | $20.79M | $49.64M | $44.99M | $51.14M | $50.33M | $52.87M | $41.38M | |
| — | $103.48M | $101.79M | $172.03M | $195.04M | $196.37M | $173.54M | $97.27M | $22.34M | $13.69M | |
| — | — | — | — | $195M | $196.4M | $173.5M | $97.3M | $22.3M | — | |
| — | $800K | $800K | $900K | $1.7M | $2.1M | $2.1M | $1.3M | $1.14M | $1.29M | |
| — | — | $19.45M | $19.45M | $11.65M | $2.71M | $2.76M | $1.37M | — | — | |
| — | — | $178.14M | $239.82M | $267.2M | — | — | $154.41M | $91.26M | $55.7M | |
| — | $173.81M | $178.14M | $239.82M | $267.2M | $245.5M | $226.34M | $154.41M | $91.26M | — | |
| — | $124.49M | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M | -$90.94M | -$55.24M | |
| — | — | 37.06% | -1.99% | -52.24% | -83.17% | -396.31% | -208.09% | -28598.43% | -11930.89% | |
| — | — | $124.36M | $14.76M | -$80.04M | -$108.76M | -$177.97M | -$102.92M | — | — | |
| — | $4.28M | $4.33M | $4.84M | $2.78M | $0 | $0 | — | — | — | |
| — | $13.52M | $13.57M | $16.97M | $17M | $5.12M | — | — | — | — | |
| — | $133.73M | $114.16M | $7.45M | -$77.47M | -$106.35M | -$180.21M | -$102.77M | -$88.24M | -$53.01M | |
| — | -$164.48M | -$173.05M | $1.7M | $551K | $1.83M | $760K | -$94K | $144K | $73K | |
| — | $298.21M | $287.2M | $5.8M | -$78M | -$108.2M | -$181M | -$102.68M | -$88.39M | -$53.08M | |
| — | — | 101.46% | 2.47% | -44.44% | -80.73% | -396.89% | -204.88% | -27794.03% | -11464.15% | |
| — | $298.16M | $287.25M | $5.84M | -$77.69M | -$108.39M | -$181.01M | -$102.68M | -$88.39M | — | |
| USD/shares | — | — | $2.14 | $0.04 | -$0.54 | -$0.76 | -$1.40 | -$0.87 | -$0.95 | — |
| USD/shares | — | — | $2.07 | $0.04 | -$0.54 | -$0.76 | -$1.40 | -$0.87 | -$0.95 | — |
| shares | — | — | 134.37M | 143.06M | 143.24M | 141.92M | 129.37M | 118.47M | 93.02M | 84.78M |
| shares | — | — | 138.7M | 146.19M | 143.24M | 141.92M | 129.37M | 118.47M | 93.02M | 84.78M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $138.4M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
7.47×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $263,841,000 | $210,095,000 | $157,958,000 | $102,460,000 | $45,488,000 | $0 | $200,000 | $345,000 |
| Japan | $19,214,000 | $25,038,000 | $17,555,000 | $31,481,000 | $0 | $50,000,000 | $0 | $0 |
| Other Country | — | — | — | $89,000 | $117,000 | $118,000 | $118,000 | — |
| China | — | — | — | — | — | — | — | $118,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $271,345,000 | $216,186,000 | $158,533,000 | $103,468,000 | $45,488,000 | $0 | $0 | $345,000 |
| License Collaboration and Royalty Revenue | $11,710,000 | $18,947,000 | $16,980,000 | $30,562,000 | $117,000 | — | — | — |
| License | — | — | — | — | — | $50,118,000 | $318,000 | $118,000 |